Ashley Dacey
Acute Care · Chandler, AZNPI 1558873208
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.4% of the total across 206 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Edwards Lifesciences at 28.1% of the total. Reporting peaked in 2024 at $2,604 and has fallen 62.5% since, to $977 in 2025. Among acute care clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 206 payments — averaging $45.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$3K
- Novartis$1K
- Abbott$584
- Boston Scientific$470
- Amgen$460
- Johnson & Johnson$451
- plus $4K from 26 others
What the payments were for
- Travel & lodging$7969%
- Food & beverage$8,48791%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 24 | $2,613 |
| Novartis | 44 | $1,103 |
| Abbott | 8 | $584 |
| Boston Scientific | 8 | $470 |
| Amgen | 10 | $460 |
| Johnson & Johnson | 15 | $451 |
| Boehringer Ingelheim | 12 | $405 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $355 |
| AstraZeneca | 6 | $317 |
| Actelion Pharmaceuticals US, Inc. | 7 | $311 |
| Atricure, Inc. | 5 | $308 |
| E.r. Squibb & Sons, L.L.C. | 8 | $293 |
| Impulse Dynamics (USA) Inc. | 4 | $201 |
| Alnylam Pharmaceuticals Inc. | 5 | $183 |
| Endotronix, Inc. | 1 | $160 |
| Sanofi-aventis U.S. LLC | 2 | $136 |
| Medtronic | 2 | $131 |
| Novo Nordisk | 2 | $108 |
| Heartflow, Inc. | 1 | $95 |
| Pfizer | 6 | $94 |
| Abiomed | 1 | $94 |
| Kestra Medical Technology Services, Inc. | 4 | $91 |
| Merck | 5 | $71 |
| Irhythm Technologies, Inc. | 3 | $49 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Altathera Pharmaceuticals LLC | 1 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| ZOLL Respicardia, Inc. | 1 | $24 |
| Chiesi USA, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPIEN 3 Ultra RESILIA$696
- Repatha$388
- PASCAL$377
- LEQVIO$355
- OPTIMIZER$282
- EVOQUE$282
- XARELTO$240
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$160
- VIGILANT X4 CRT-D$145
- TRICLIP$145
- MitraClip$144
- CARDIOMEMS$144
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$134
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$130
- WAINUA$125
- JARDIANCE$124
- UPTRAVI$122
- OPSUMIT$122
- WATCHMAN Access System$117
- ONPATTRO$115
How this compares
$9,284 in reported general payments places this provider in the 95th percentile of 482 acute care providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 86 | $129,217 |
| EntrestoSacubitril/Valsartan | 65 | $79,217 |
| JardianceEmpagliflozin | 87 | $70,735 |
| FarxigaDapagliflozin Propanediol | 29 | $29,484 |
| XareltoRivaroxaban | 26 | $27,711 |
| Repatha SureclickEvolocumab | 13 | $20,491 |
| Ranolazine ErRanolazine | 15 | $4,119 |
| Atorvastatin Calcium | 177 | $1,861 |
| Metoprolol Succinate | 125 | $1,625 |
| Rosuvastatin Calcium | 98 | $1,480 |
| Ezetimibe | 39 | $1,224 |
| Eplerenone | 21 | $1,142 |
| Carvedilol | 107 | $1,057 |
| Amlodipine Besylate | 137 | $981 |
| Potassium Chloride | 35 | $936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $94 | $129,21786 claims |
| NovartisEntresto | $1,103 | $79,21765 claims |
| Boehringer IngelheimJardiance | $405 | $70,73587 claims |
| AstraZenecaFarxiga | $317 | $29,48429 claims |
| Johnson & JohnsonXarelto | $451 | $27,71126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 482 acute care providers in Arizona.
Other acute care in Chandler
- Dawn FickasChandler$10K
- Erica WhettenChandler$4K
- Nicole CiffoneTucson$162K
- Kim KrmpoticPhoenix$79K
- Stephanie WilsonScottsdale$37K
- Laura Cook-GongoraPhoenix$32K
- Cathy PaynePhoenix$26K
- Chandra SorrellePhoenix$16K
- Nicole RauscherPhoenix$12K
- Seania BristolMesa$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.